US-based biopharmaceutical company Synlogic signed a research and development agreement with an unnamed pharmaceutical company yesterday.
The partnership is set to last for several years and focus on treatments for certain kinds of inflammatory bowel disease, such as ulcerative colitis and Crohn’s disease. Synlogic has not revealed whether the pharmaceutical company has also backed the previously disclosed series A round.
Synlogic raised $34.4m in series A funding over two tranches last year, initially securing $29.4m from Atlas Venture and New Enterprise Associates in July before attracting a $5m extension from Bill and Melinda Gates Foundation in October.
Synlogic currently has two lead drug candidates targeting rare metabolic disorders. The company has revealed it will use the series A funding to advance those candidates into clinical trials.
The company also plans to enter more partnerships with other biotechnology and pharmaceutical companies to extend its pipeline.